Food intake and energy expenditure are tightly regulated by the brain, in a homeostatic process that integrates diverse hormonal, neuronal and metabolic signals. The gastrointestinal tract is an important source of such signals, which include several hormones released by specialized enteroendocrine cells. These hormones exert powerful effects on appetite and energy expenditure. This Review addresses the physiological roles of peptide YY, pancreatic polypeptide, islet amyloid polypeptide, glucagon-like peptide 1, glucagon, oxyntomodulin, cholecystokinin and ghrelin and discusses their potential as targets for the development of novel treatments for obesity.
The history of pharmacological therapies for obesity is characterized principally by inefficacy and marked adverse effects
Robust weight loss can be achieved through bariatric surgery, with associated changes in the intestinal hormonal response to calorie intake
Gut hormones such as glucagon-like peptide 1, peptide YY, pancreatic polypeptide, glucagon and islet amyloid polypeptide act in an integrated fashion to modulate appetite and energy expenditure
A potential therapy for obesity might be based on the concept of pharmacological mimicry of the hormonal milieu after bariatric surgery
Development of such therapies will, however, require improved understanding of the interactions between hormones and of their integration with other signals of nutritional status
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Cell Death & Disease Open Access 24 August 2017
The intestinal distribution pattern of appetite- and glucose regulatory peptides in mice, rats and pigs
BMC Research Notes Open Access 02 February 2016
Lipids in Health and Disease Open Access 29 September 2015
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Hutton, B. & Fergusson, D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am. J. Clin. Nutr. 80, 1461–1468 (2004).
Adams, T. D. et al. Long-term mortality after gastric bypass surgery. N. Engl. J. Med. 357, 753–761 (2007).
Sjöström, L. et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N. Engl. J. Med. 357, 741–752 (2007).
Dixon, A. F., Dixon, J. B. & O'Brien, P. E. Laparoscopic adjustable gastric banding induces prolonged satiety: a randomized blind crossover study. J. Clin. Endocrinol. Metab. 90, 813–819 (2005).
Kenler, H. A., Brolin, R. E. & Cody, R. P. Changes in eating behavior after horizontal gastroplasty and Roux-en-Y gastric bypass. Am. J. Clin. Nutr. 52, 87–92 (1990).
Gan, S. S., Talbot, M. L. & Jorgensen, J. O. Efficacy of surgery in the management of obesity-related type 2 diabetes mellitus. ANZ J. Surg. 77, 958–962 (2007).
Kellum, J. M. et al. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann. Surg. 211, 763–770 (1990).
le Roux, C. W. et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann. Surg. 243, 108–114 (2006).
Chan, J. L., Heist, K., DePaoli, A. M., Veldhuis, J. D. & Mantzoros, C. S. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J. Clin. Invest. 111, 1409–1421 (2003).
Tatemoto, K. & Mutt, V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 285, 417–418 (1980).
Mentlein, R., Dahms, P., Grandt, D. & Kruger, R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul. Pept. 49, 133–144 (1993).
Grandt, D. et al. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1–36 and PYY 3–36. Regul. Pept. 51, 151–159 (1994).
Keire, D. A., Bowers, C. W., Solomon, T. E. & Reeve, J. R. Jr. Structure and receptor binding of PYY analogs. Peptides 23, 305–321 (2002).
Adrian, T. E. et al. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89, 1070–1077 (1985).
Batterham, R. L. et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab. 4, 223–233 (2006).
Pedersen-Bjergaard, U. et al. Influence of meal composition on postprandial peripheral plasma concentrations of vasoactive peptides in man. Scand. J. Clin. Lab. Invest. 56, 497–503 (1996).
Degen, L. et al. Effect of CCK-1 receptor blockade on ghrelin and PYY secretion in men. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292, R1391–R1399 (2007).
Adrian, T. E. et al. Effect of peptide YY on gastric, pancreatic, and biliary function in humans. Gastroenterology 89, 494–499 (1985).
Savage, A. P., Adrian, T. E., Carolan, G., Chatterjee, V. K. & Bloom, S. R. Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 28, 166–170 (1987).
Hoentjen, F., Hopman, W. P. & Jansen, J. B. Effect of circulating peptide YY on gallbladder emptying in humans. Scand. J. Gastroenterol. 36, 1086–1091 (2001).
Koda, S. et al. The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. Endocrinology 146, 2369–2375 (2005).
Batterham, R. L. et al. Gut hormone PYY(3–36) physiologically inhibits food intake. Nature 418, 650–654 (2002).
Chelikani, P. K., Haver, A. C. & Reidelberger, R. D. Intermittent intraperitoneal infusion of peptide YY(3–36) reduces daily food intake and adiposity in obese rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293, R39–R46 (2007).
Pittner, R. A. et al. Effects of PYY[3–36] in rodent models of diabetes and obesity. Int. J. Obes. Relat. Metab. Disord. 28, 963–971 (2004).
Batterham, R. L. et al. Inhibition of food intake in obese subjects by peptide YY3–36. N. Engl. J. Med. 349, 941–948 (2003).
Degen, L. et al. Effect of peptide YY3–36 on food intake in humans. Gastroenterology 129, 1430–1436 (2005).
le Roux, C. W. et al. Supraphysiological doses of intravenous PYY3–36 cause nausea, but no additional reduction in food intake. Ann. Clin. Biochem. 45, 93–95 (2008).
Sloth, B., Holst, J. J., Flint, A., Gregersen, N. T. & Astrup, A. Effects of PYY1–36 and PYY3–36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am. J. Physiol. Endocrinol. Metab. 292, E1062–E1068 (2007).
Gantz, I. et al. Efficacy and safety of intranasal peptide YY3–36 for weight reduction in obese adults. J. Clin. Endocrinol. Metab. 92, 1754–1757 (2007).
Beglinger, C. et al. Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3–36: a proof-of-concept study in healthy subjects. Clin. Pharmacol. Ther. 84, 468–474 (2008).
le Roux, C. W. et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann. Surg. 246, 780–785 (2007).
Adrian, T. E. et al. Distribution and release of human pancreatic polypeptide. Gut 17, 940–944 (1976).
Larsson, L. I., Sundler, F. & Håkanson, R. Immunohistochemical localization of human pancreatic polypeptide (HPP) to a population of islet cells. Cell Tissue Res. 156, 167–171 (1975).
Schwartz, T. W. et al. Vagal, cholinergic regulation of pancreatic polypeptide secretion. J. Clin. Invest. 61, 781–789 (1978).
Gerald, C. et al. A receptor subtype involved in neuropeptide-Y-induced food intake. Nature 382, 168–171 (1996).
Ueno, N. et al. Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. Gastroenterology 117, 1427–1432 (1999).
Asakawa, A. et al. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 124, 1325–1336 (2003).
McTigue, D. M. & Rogers, R. C. Pancreatic polypeptide stimulates gastric motility through a vagal-dependent mechanism in rats. Neurosci. Lett. 188, 93–96 (1995).
Batterham, R. L. et al. Pancreatic polypeptide reduces appetite and food intake in humans. J. Clin. Endocrinol. Metab. 88, 3989–3992 (2003).
Schmidt, P. T. et al. A role for pancreatic polypeptide in the regulation of gastric emptying and short-term metabolic control. J. Clin. Endocrinol. Metab. 90, 5241–5246 (2005).
Berntson, G. G., Zipf, W. B., O'Dorisio, T. M., Hoffman, J. A. & Chance, R. E. Pancreatic polypeptide infusions reduce food intake in Prader–Willi syndrome. Peptides 14, 497–503 (1993).
Cooper, G. J. et al. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc. Natl Acad. Sci. USA 84, 8628–8632 (1987).
Christopoulos, G. et al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol. Pharmacol. 56, 235–242 (1999).
Silvestre, R. A. et al. Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. Am. J. Physiol. Endocrinol. Metab. 280, E443–E449 (2001).
Young, A. A., Gedulin, B. R. & Rink, T. J. Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7–36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism 45, 1–3 (1996).
Gedulin, B. R., Jodka, C. M., Herrmann, K. & Young, A. A. Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187. Regul. Pept. 137, 121–127 (2006).
Furrer, D., Kaufmann, K., Reusch, C. E. & Lutz, T. A. Amylin reduces plasma glucagon concentration in cats. Vet. J. 184, 236–240 (2010).
Lutz, T. A. et al. Lesion of the area postrema/nucleus of the solitary tract (AP/NTS) attenuates the anorectic effects of amylin and calcitonin gene-related peptide (CGRP) in rats. Peptides 19, 309–317 (1998).
Roth, J. D. et al. Combination therapy with amylin and peptide YY[3–36] in obese rodents: anorexigenic synergy and weight loss additivity. Endocrinology 148, 6054–6061 (2007).
Bhavsar, S., Watkins, J. & Young, A. Synergy between amylin and cholecystokinin for inhibition of food intake in mice. Physiol. Behav. 64, 557–561 (1998).
Levetan, C. et al. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care 26, 1–8 (2003).
Roth, J. D. et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies. Proc. Natl Acad. Sci. USA 105, 7257–7262 (2008).
Ravussin, E. et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 17, 1736–1743 (2009).
Orskov, C., Rabenhøj, L., Wettergren, A., Kofod, H. & Holst, J. J. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43, 535–539 (1994).
Herrmann, C. et al. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56, 117–126 (1995).
Mojsov, S. et al. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J. Biol. Chem. 261, 11880–11889 (1986).
Rocca, A. S. & Brubaker, P. L. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 140, 1687–1694 (1999).
Chu, Z. L. et al. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 149, 2038–2047 (2008).
Kreymann, B., Williams, G., Ghatei, M. A. & Bloom, S. R. Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet 2, 1300–1304 (1987).
Gutniak, M., Orskov, C., Holst, J. J., Ahrén, B. & Efendic, S. Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 326, 1316–1322 (1992).
Willms, B. et al. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7–36) amide in type 2 (noninsulin-dependent) diabetic patients. J. Clin. Endocrinol. Metab. 81, 327–332 (1996).
Flint, A., Raben, A., Astrup, A. & Holst, J. J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 101, 515–520 (1998).
Zander, M., Madsbad, S., Madsen, J. L. & Holst, J. J. Effect of 6-week course of glucagon-like peptide 1 on glycemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359, 824–830 (2002).
Kieffer, T. J., McIntosh, C. H. & Pederson, R. A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136, 3585–3596 (1995).
Eng, J., Kleinman, W. A., Singh, L., Singh, G. & Raufman, J. P. Isolation and characterization of exendin-4, an exendin-3 analog, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 267, 7402–7405 (1992).
Russell-Jones, D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analog. Mol. Cell. Endocrinol. 297, 137–140 (2009).
Ratner, R. E. et al. Long-term effects of exenatide therapy over 82 weeks on glycemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 8, 419–428 (2006).
Astrup, A. et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374, 1606–1616 (2009).
Nauck, M. A. et al. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care 32, 1237–1243 (2009).
Astrup, A., Rössner, S., Van Gaal, L. & Rasmusen, M. F. Liraglutide for weight loss in obese people—Authors' reply. Lancet 375, 552–553 (2010).
Knudsen, L. B. et al. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc. Natl Acad. Sci. USA 104, 937–942 (2007).
ClinicalTrials.gov A two part trial investigating the safety of NN9924 in healthy male subjects [online], (2010).
Overton, H. A. et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 3, 167–175 (2006).
Jones, R. M., Leonard, J. N., Buzard, D. J. & Lehmann, J. GPR119 agonists for the treatment of type 2 diabetes. Expert Opin. Ther. Pat. 19, 1339–1359 (2009).
de Jong, A., Strubbe, J. H. & Steffens, A. B. Hypothalamic influence on insulin and glucagon release in the rat. Am. J. Physiol. 233, E380–E388 (1977).
Dencker, H., Hedner, P., Holst, J. & Tranberg, K. G. Pancreatic glucagon response to an ordinary meal. Scand. J. Gastroenterol. 10, 471–474 (1975).
Langhans, W., Pantel, K., Muller-Schell, W., Eggenberger, E. & Scharrer, E. Hepatic handling of pancreatic glucagon and glucose during meals in rats. Am. J. Physiol. 247, R827–R832 (1984).
Deacon, C. F. et al. Differential regional metabolism of glucagon in anesthetized pigs. Am. J. Physiol. Endocrinol. Metab. 285, E552–E560 (2003).
Geary, N., Le Sauter, J. & Noh, U. Glucagon acts in the liver to control spontaneous meal size in rats. Am. J. Physiol. 264, R116–R122 (1993).
Geary, N. & Smith, G. P. Selective hepatic vagotomy blocks pancreatic glucagon's satiety effect. Physiol. Behav. 31, 391–394 (1983).
Schulman, J. L., Carleton, J. L., Whitney, G. & Whitehorn, J. C. Effect of glucagon on food intake and body weight in man. J. Appl. Physiol. 11, 419–421 (1957).
Penick, S. B. & Hinkle, L. E. Jr. Depression of food intake induced in healthy subjects by glucagon. N. Engl. J. Med. 264, 893–897 (1961).
Geary, N., Kissileff, H. R., Pi-Sunyer, F. X. & Hinton, V. Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men. Am. J. Physiol. 262, R975–R980 (1992).
Glick, G., Parmley, W. W., Wechsler, A. S. & Sonnenblick, E. H. Glucagon. Its enhancement of cardiac performance in the cat and dog and persistence of its inotropic action despite beta-receptor blockade with propranolol. Circ. Res. 22, 789–799 (1968).
Liljenquist, J. E. et al. Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men. J. Clin. Invest. 53, 190–197 (1974).
Pocai, A. et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58, 2258–2266 (2009).
Day, J. W. et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat. Chem. Biol. 5, 749–757 (2009).
Borg, C. M. et al. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br. J. Surg. 93, 210–215 (2006).
Ghatei, M. A., Uttenthal, L. O., Christofides, N. D., Bryant, M. G. & Bloom, S. R. Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. J. Clin. Endocrinol. Metab. 57, 488–495 (1983).
Polak, J. M., Bloom, S., Coulling, I. & Pearse, A. G. Immunofluorescent localization of enteroglucagon cells in the gastrointestinal tract of the dog. Gut 12, 311–318 (1971).
Biedzinski, T. M., Bataille, D., Devaux, M. A. & Sarles, H. The effect of oxyntomodulin (glucagon-37) and glucagon on exocrine pancreatic secretion in the conscious rat. Peptides 8, 967–972 (1987).
Cohen, M. A. et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J. Clin. Endocrinol. Metab. 88, 4696–4701 (2003).
Dubrasquet, M., Bataille, D. & Gespach, C. Oxyntomodulin (glucagon-37 or bioactive enteroglucagon): a potent inhibitor of pentagastrin-stimulated acid secretion in rats. Biosci. Rep. 2, 391–395 (1982).
Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J. & Holst, J. J. Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions. Dig. Dis. Sci. 34, 1411–1419 (1989).
Wynne, K. et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 54, 2390–2395 (2005).
Wynne, K. et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int. J. Obes. (Lond.) 30, 1729–1736 (2006).
Bataille, D. et al. Isolation of glucagon-37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Characterization of the peptide. FEBS Lett. 146, 79–86 (1982).
Baggio, L. L., Huang, Q., Brown, T. J. & Drucker, D. J. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127, 546–558 (2004).
Dakin, C. L. et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology 142, 4244–4250 (2001).
Druce, M. R. et al. Investigation of structure-activity relationships of Oxyntomodulin (Oxm) using Oxm analogs. Endocrinology 150, 1712–1722 (2009).
Zhu, L. et al. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1–38). J. Biol. Chem. 278, 22418–22423 (2003).
Liddle, R. A., Goldfine, I. D., Rosen, M. S., Taplitz, R. A. & Williams, J. A. Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J. Clin. Invest. 75, 1144–1152 (1985).
Polak, J. M. et al. Identification of cholecystokinin-secreting cells. Lancet 2, 1016–1018 (1975).
Schwartz, G. J., McHugh, P. R. & Moran, T. H. Integration of vagal afferent responses to gastric loads and cholecystokinin in rats. Am. J. Physiol. 261, R64–R69 (1991).
Takahashi, T., May, D. & Owyang, C. Cholinergic dependence of gallbladder response to cholecystokinin in the guinea pig in vivo. Am. J. Physiol. 261, G565–G569 (1991).
Fried, M. et al. Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide. Gastroenterology 101, 503–511 (1991).
Beglinger, S. et al. Role of fat hydrolysis in regulating glucagon-like peptide-1 secretion. J. Clin. Endocrinol. Metab. 95, 879–886 (2010).
Barden, N. et al. Regional distributions of somatostatin and cholecystokinin-like immunoreactivities in rat and bovine brain. Peptides 2, 299–302 (1981).
Gibbs, J., Young, R. C. & Smith, G. P. Cholecystokinin elicits satiety in rats with open gastric fistulas. Nature 245, 323–325 (1973).
West, D. B., Fey, D. & Woods, S. C. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am. J. Physiol. 246, R776–R787 (1984).
Kissileff, H. R., Pi-Sunyer, F. X., Thornton, J. & Smith, G. P. C-terminal octapeptide of cholecystokinin decreases food intake in man. Am. J. Clin. Nutr. 34, 154–160 (1981).
Jordan, J. et al. Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients. Clin. Pharmacol. Ther. 83, 281–287 (2008).
Asin, K. E. et al. Behavioral effects of A71623, a highly selective CCK-A agonist tetrapeptide. Am. J. Physiol. Regul. Integr. Comp. Physiol. 263, R125–R135 (1992).
Simmons, R. D., Kaiser, F. C. & Hudzik, T. J. Behavioral effects of AR-R 15849, a highly selective CCK-A agonist. Pharmacol. Biochem. Behav. 62, 549–557 (1999).
Merino, B., Cano, V., Guzmán, R., Somoza, B. & Ruiz-Gayo, M. Leptin-mediated hypothalamic pathway of cholecystokinin (CCK-8) to regulate body weight in free-feeding rats. Endocrinology 149, 1994–2000 (2008).
Date, Y. et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141, 4255–4261 (2000).
Kojima, M. et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656–660 (1999).
Yang, J., Brown, M. S., Liang, G., Grishin, N. V. & Goldstein, J. L. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 132, 387–396 (2008).
Tschöp, M., Smiley, D. L. & Heiman, M. L. Ghrelin induces adiposity in rodents. Nature 407, 908–913 (2000).
Cummings, D. E. et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50, 1714–1719 (2001).
Cummings, D. E., Frayo, R. S., Marmonier, C., Aubert, R. & Chapelot, D. Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food-related cues. Am. J. Physiol. Endocrinol. Metab. 287, E297–E304 (2004).
Wren, A. M. et al. Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab. 86, 5992 (2001).
Tschöp, M. et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 50, 707–709 (2001).
English, P. J., Ghatei, M. A., Malik, I. A., Bloom, S. R. & Wilding, J. P. Food fails to suppress ghrelin levels in obese humans. J. Clin. Endocrinol. Metab. 87, 2984 (2002).
Druce, M. R. et al. Ghrelin increases food intake in obese as well as lean subjects. Int. J. Obes. (Lond.) 29, 1130–1136 (2005).
Neary, N. M. et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 89, 2832–2836 (2004).
Nass, R. et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann. Intern. Med. 149, 601–611 (2008).
Rosenbaum, M. et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J. Clin. Invest. 115, 3579–3586 (2005).
Chikunguwo, S. et al. Influence of obesity and surgical weight loss on thyroid hormone levels. Surg. Obes. Relat. Dis. 3, 631–635 (2007).
S. R. Bloom declares an association with the following company: Wyeth Pharmaceuticals. S. R. Bloom is the inventor of patents describing the use of gut hormones and their analogs and derivatives in the treatment of obesity, and is a consultant for Thiakis, a subsidiary of Wyeth Pharmaceuticals. The other authors declare no competing interests.
About this article
Cite this article
Field, B., Chaudhri, O. & Bloom, S. Bowels control brain: gut hormones and obesity. Nat Rev Endocrinol 6, 444–453 (2010). https://doi.org/10.1038/nrendo.2010.93
The Implication of Gut Hormones in the Regulation of Energy Homeostasis and Their Role in the Pathophysiology of Obesity
Current Obesity Reports (2020)
Acute increases in serum colonic short-chain fatty acids elicited by inulin do not increase GLP-1 or PYY responses but may reduce ghrelin in lean and overweight humans
European Journal of Clinical Nutrition (2017)
Cell Death & Disease (2017)
Nature Reviews Endocrinology (2017)